What are common side effects of Opdivo plus Yervoy in lung cancer?
Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)
What serious side effects occurred with Opdivo plus Yervoy in Checkmate 227?
Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)
What are common side effects of Opdivo, Yervoy, and chemo (Checkmate 9LA)?
Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)
What serious side effects occurred with Opdivo, Yervoy, and chemotherapy (Checkmate 9LA)?
Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)
Note: Checkmate 67T enrolled adults with advanced or metastatic clear cell renal cell carcinoma; the safety page for previously treated metastatic NSCLC presents these data.
How common is pneumonitis with Opdivo plus Yervoy in NSCLC?
Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)